Lacour, B., Di Giulio, S., Chanard, J., Ciancioni, C., Haguet, M., Lebkiri, B., Basile, C., Drueke, T., Assan, R., and Funck-Brentano, J
Acta Med Iran
They cluster in the first few weeks and around dose increases, then taper
So, when lawmakers are warned that compounded GLP-1s are flooding the market with unsafe ingredients, a serious policymaker should ask: Where is the evidence that state-licensed pharmacies are responsible
Indeed, a well-documented phenomenon undoubtedly contributing to the resistance of these drugs in producing a greater duration and magnitude of weight loss is the host of counter-regulatory metabolic and neuroendocrine changes that occur with weight loss 54